← SynDRA
NOLATREXED
SynDRA canonical compound SYN0004151 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | TYMS |
|---|
| Mechanism of action | thymidylate synthase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- TYMS ANTAGONIST
- thymidylate synthase inhibitor
- Candi TMP1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ADCY9
- AHR
- SYK
- PNMT
- NSD2
- NNMT
- NF2L2
- KSYK
- HNMT
- GNMT
- GLI3
- GCR
- GAMT
- ESRRA
- ESR1
- CP3A4
- CP2D6
- CP2CJ
- CP2C9
- CP1A2
- CP19A
- COMT
- ATXN2
- TP53
Drug classes
- Antimetabolites, Antineoplastic
- Enzyme Inhibitors
- Folic Acid Antagonists
Cross-references
Synonyms
- Thymitaq
- AG-337
- ZX-337
- Nolatrexed (intravenous), EXIMIAS
- K75ZUN743Q
- 2-Amino-6-methyl-5-(4-pyridylthio)-4(3H)-quinazolinone
- nolatrexedum
- RefChem:166398
- DTXCID4028256
- Nolatrexed [INN]
- 2-amino-6-methyl-5-(pyridin-4-ylthio)quinazolin-4(3H)-one
- 4(1H)-Quinazolinone, 2-amino-6-methyl-5-(4-pyridinylthio)-
- 2-amino-6-methyl-5-pyridin-4-ylsulfanyl-3H-quinazolin-4-one
- 2-Azanyl-6-Methyl-5-Pyridin-4-Ylsulfanyl-3h-Quinazolin-4-One
- AG-337;Nolatrexed dihydrochloride
- NSC648316
- NCGC00181023-01
- UNII-K75ZUN743Q
- NOLATREXED [MI]
- Nolatrexed (AG-337)?
- NOLATREXED [MART.]
- NOLATREXED [WHO-DD]
- SCHEMBL18489
- SCHEMBL710461
- orb1303041
- TQR1204
- 2-Amino-6-methyl-5-(4-pyridinylthio)-4(1H)-quinazolinone
- HMS3744I03
- BDBM50046657
- MFCD26960887
- AKOS025401776
- NCGC00181023-02
- NCGC00181023-03
- NCGC00181023-04
- AC-25494
- NCI60_016753
- TS-09007
- DB-063698
- CS-0007743
Look up NOLATREXED in the interactive SynDRA portal →